Context for CRISPR Therapeutics stock CRISPR Therapeutics (CRSP) trades around US$49.51, with recent returns ranging from a 1 day gain of about 1.4% to a past month decline of roughly 13.6% and a past ...

Colossal Biosciences is establishing standards for how biotechnology can responsibly support biodiversity conservation in an ...

Christos Soteriou was 29 when he needed a quadruple bypass surgery.

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $48.81, moving +2.61% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.72%. Elsewhere, the Dow ...

Crispr Therapeutics AG looks set for 2026 revenue inflection as Casgevy ramps; strong efficacy, undervalued shares, robust ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics AG (CRSP) is rated Buy, with a 12-month price target of $64.58, driven by CASGEVY's commercial ramp and a ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the stocks that could 10x over the next 10 years. Piper Sandler boosted its ...

CRISPR Cas9 gene therapy explained with DNA scissors, hereditary diseases treatment, and designer babies ethical dilemmas ...

What did the recent study using the crispr gene editing technique actually entail, and what did we learn from it? Hosted by: Hank Green Dooblydoo thanks go to the following Patreon supporters: Kevin ...

By identifying the genes that allow plants to pause growth during stress and restart, we can help ensure crops produce ...

Researchers at Cornell University have developed a powerful new genetic toolkit that allows scientists to study how genes ...